Skip to main content
Journal of Bacteriology logoLink to Journal of Bacteriology
. 2012 Nov;194(22):6154–6161. doi: 10.1128/JB.01317-12

A Conserved UDP-Glucose Dehydrogenase Encoded outside the hasABC Operon Contributes to Capsule Biogenesis in Group A Streptococcus

Jason N Cole a,b, Ramy K Aziz c,d, Kirsten Kuipers a,g, Anjuli M Timmer a, Victor Nizet a,e,f, Nina M van Sorge a,g,
PMCID: PMC3486382  PMID: 22961854

Abstract

Group A Streptococcus (GAS) is a human-specific bacterial pathogen responsible for serious morbidity and mortality worldwide. The hyaluronic acid (HA) capsule of GAS is a major virulence factor, contributing to bloodstream survival through resistance to neutrophil and antimicrobial peptide killing and to in vivo pathogenicity. Capsule biosynthesis has been exclusively attributed to the ubiquitous hasABC hyaluronan synthase operon, which is highly conserved across GAS serotypes. Previous reports indicate that hasA, encoding hyaluronan synthase, and hasB, encoding UDP-glucose 6-dehydrogenase, are essential for capsule production in GAS. Here, we report that precise allelic exchange mutagenesis of hasB in GAS strain 5448, a representative of the globally disseminated M1T1 serotype, did not abolish HA capsule synthesis. In silico whole-genome screening identified a putative HasB paralog, designated HasB2, with 45% amino acid identity to HasB at a distant location in the GAS chromosome. In vitro enzymatic assays demonstrated that recombinant HasB2 is a functional UDP-glucose 6-dehydrogenase enzyme. Mutagenesis of hasB2 alone slightly decreased capsule abundance; however, a ΔhasB ΔhasB2 double mutant became completely acapsular. We conclude that HasB is not essential for M1T1 GAS capsule biogenesis due to the presence of a newly identified HasB paralog, HasB2, which most likely resulted from gene duplication. The identification of redundant UDP-glucose 6-dehydrogenases underscores the importance of HA capsule expression for M1T1 GAS pathogenicity and survival in the human host.

INTRODUCTION

The Gram-positive bacterial pathogen Streptococcus pyogenes, commonly referred to as group A Streptococcus (GAS), is the etiologic agent of numerous human diseases. Clinical manifestations range from benign skin infections, such as impetigo and pharyngitis (∼700 million cases per year worldwide), to potentially life-threatening invasive infections, including necrotizing fasciitis and streptococcal toxic shock-like syndrome (∼650,000 cases per year worldwide), with an associated mortality of 25% (9). Serious postinfectious sequelae, including acute poststreptococcal glomerulonephritis and rheumatic fever, may also develop following recurrent GAS infections. The resurgence of severe invasive GAS diseases over the past 30 years (10) correlates with the isolation of the globally disseminated serotype M1T1 GAS.

GAS strains express an assortment of surface-associated molecules that contribute to pathogenesis, including a high-molecular-mass hyaluronic acid (HA) capsule consisting of a polymer of alternating glucuronic acid and β-1,3-linked N-acetylglucosamine residues (34). The capsule is essentially identical to mammalian HA expressed abundantly on cell surfaces, connective tissue, and the extracellular matrix milieu. The molecular mimicry of host structures enables GAS to avoid detection by the host immune system (14) and accounts for the poor immunogenicity of the GAS capsule in humans (27). A primary role of HA capsule is to provide a physical barrier that promotes bacterial survival through interference with host immune responses, including antibody access to epitopes on the bacterial surface (21), complement deposition (16), and opsonophagocytosis (7, 16, 26). Also, capsule promotes GAS survival in neutrophil extracellular traps (NETs) through enhanced resistance to cathelicidin antimicrobial peptide LL-37, a major constituent of NETs (11). Consequently, acapsular GAS mutants are sensitive to phagocytic killing in human blood in vitro and have reduced virulence in murine models of GAS invasive infection compared with encapsulated wild-type (WT) strains (36, 4749). In addition to its role in systemic infection, capsular HA binds CD44 on host cell keratinocytes to promote GAS adherence to pharyngeal epithelial cells (40) and contributes to pharyngeal colonization in a mouse model (15). Together, these studies confirm a central role for capsule in GAS pathogenicity.

HA capsule biosynthesis in GAS is coordinated by the ubiquitous and highly conserved hasABC operon (13, 22). Hyaluronate synthase (encoded by hasA) is a membrane-associated enzyme that forms the linear HA polymer by the alternate addition of N-acetylglucosamine and glucuronic acid residues from their respective UDP-sugar precursors (19, 23). UDP-glucose 6-dehydrogenase (encoded by hasB) forms UDP-glucuronic acid from UDP-glucose in the presence of NAD (24), while UDP-glucose pyrophosphorylase (glucose-1-phosphate uridylyltransferase; encoded by hasC) catalyzes the production of UDP-glucose from glucose-1-phosphate and UTP (12). The hasABC operon is transcribed as a single mRNA transcript from a promoter located upstream of the first gene in the operon, hasA (1, 12), with maximal expression occurring in exponential growth phase (13, 45). The region of −10 to −35 of the hasABC promoter plays a central role in determining promoter strength and capsule expression levels in GAS (1).

GAS capsule expression is strongly upregulated in human blood (29, 39), and highly encapsulated, or mucoid, isolates are frequently associated with pharyngeal persistence, acute rheumatic fever, and severe invasive human diseases (32, 41). Capsule is also indispensable for the in vivo selection of hypervirulent M1T1 GAS variants harboring mutations within the two-component regulator covRS (11), also known as csrRS (5, 35). Mutations within covRS transcriptionally affect ∼10 to 15% of the genes within the GAS genome (28, 43), resulting in enhanced expression of the hasABC operon and an array of neutrophil resistance genes (10, 44). Enhanced HA capsule expression concomitantly reduces adherence to keratinocytes, extracellular matrix binding, and biofilm formation (31), preventing the dissemination of hypervirulent covRS mutant M1T1 GAS among the human population (31).

Previous reports concluded that HasA and HasB are uniquely required for GAS capsule production (3, 18), while HasC is not essential (3, 19). However, these studies inferred the contribution of HasB to GAS HA production by using either heterologous expression systems or Tn916 transposon mutants with polar effects on downstream gene expression levels. Here, we targeted the hasB gene in serotype M1T1 GAS by precise allelic exchange mutagenesis to directly address the role of HasB in capsule biosynthesis. Our results indicate that HasB is a nonessential enzyme for capsule synthesis in M1T1 GAS. We report the identification and characterization of a novel UDP-glucose 6-dehydrogenase, designated HasB2, which can compensate for a nonfunctional HasB enzyme.

MATERIALS AND METHODS

Bacterial strains and growth conditions.

GAS strain 5448, a representative of the globally disseminated serotype M1T1 clone, was isolated from a patient with toxic shock-like syndrome and necrotizing fasciitis (33) and is here designated the wild-type (WT) strain. The isogenic ΔhasA insertional mutant of this WT strain was described previously (31). GAS strains were routinely propagated at 37°C on Todd-Hewitt agar (THA) or in liquid cultures of Todd-Hewitt broth (THB) (Hardy Diagnostics) under static conditions. When required, growth medium was supplemented with 5 μg/ml erythromycin (Em) or 2 μg/ml chloramphenicol (Cm). Escherichia coli strain BL21 Star (DE3) (Invitrogen) was grown at 37°C on Luria-Bertani (LB) (Hardy Diagnostics) agar with 50 μg/ml kanamycin (Km) or in liquid cultures of LB supplemented with 50 μg/ml Km with orbital rotation at 220 rpm.

Allelic exchange mutagenesis of hasB.

To construct the precise in-frame allelic exchange mutant of hasB (GenBank GeneID 3571024), the upstream and downstream regions of hasB were PCR amplified from the WT GAS chromosome using the primer pair hasB-up-for (5′-GGCTCTAGAGGACGCACTGTCTACCAATC-3′) and hasB-up-rev-cat (5′-GGTGGTATATCCAGTGATTTTTTTCTCCATCAATCTCTTCCTCATTAAAA-3′, with a 30-bp 5′ extension matching the 5′ end of the chloramphenicol acetyltransferase [cat] gene) and the pair hasB-dn-for-cat (5′-ATCTGCGATGAGTGGCAGGGCGGGGCGTAACCATGTCTTCATCTATAACA-3′, with 30 bp 5′ extension matching 3′ end of the cat gene) and hasB-dn-rev (5′-GCCGGATCCCCTCTAATTTCAACAGTTCA-3′). Purified upstream and downstream PCR products, in addition to the cat PCR product, were amplified with Pfu Ultra II (Stratagene) to yield a fusion product in which cat precisely replaced hasB. This fusion product was cloned into the temperature-sensitive Emr plasmid pHY304 (38) and electroporated into the WT strain (17), and the transformants were selected by growth on THA supplemented with 5 μg/ml Em for 2 days at 30°C. Single crossover recombination was selected for by shifting to the nonpermissive temperature (37°C) while maintaining Em selection and was confirmed by PCR. Selective pressure was relaxed by serial passage at 30°C without antibiotics, and double crossovers were identified by screening for a Cmr Ems phenotype. The in-frame allelic exchange of hasB with cat in the GAS chromosome was verified by PCR using hasB- and cat-specific primers.

Insertional mutagenesis of hasB2.

Genetic mutation of hasB2 (GenBank GeneID 3572465) in GAS was performed by PCR amplifying a 445-bp fragment starting from 122 bp downstream of the hasB2 ATG start codon using primers Forw-XhoI (5′-GCGCTCGAGGCAATCCCCTCTTAAAGAAGCAG-3′) and Rev-BamHI (5′-GCGGGATCCTCGCTTCTGCTTCAGAAGAGCC-3′) (underlining indicates restriction sequences). The fragment was cloned into temperature-sensitive plasmid pHY304 and transformed into the electrocompetent WT or ΔhasB strain, and single crossover mutants ΔhasB2 and ΔhasB ΔhasB2 were generated following temperature shifting and antibiotic selection (Emr), as described above. Plasmid integration was confirmed by PCR using primers Forw-XhoI and Rev-confirm (5′-CCGAAAGAAGGATTATTGTGCG-3′). Revertant strains, here designated the ΔhasB2R1 and ΔhasB ΔhasB2R1 strains, were generated by serial passage at 30°C for 2 days in THB without antibiotic selection, prior to the plating of serial dilutions onto THA and overnight incubation at 37°C. Loss of the integrated plasmid from the chromosome was identified by screening for Ems colonies. Restoration of the hasB2 allele was confirmed by the HA capsule assay and PCR using primers Forw (5′-GGCTGGAGACAAGAACTAAAGACT-3′) and Rev-confirm to obtain a 974-bp amplicon.

Cloning and recombinant protein expression.

The hasB2 and hasB genes were PCR amplified from the WT GAS chromosome using the primer pair HasB2-F (5′-GGGAATTCATGAAAATTACAGTTGTAG-3′) and HasB2-R (5′-GGGAATTCTTAATCATACTGAAAAATATCA-3′) and the pair HasB-F (5′-GGGAATTCATGAAAATAGCAGTTG-3′) and HasB-R (5′-GGGAATTCCTAGTCTCTATTAAAAATATCTCTAC-3′). Purified PCR products were cloned into the Kmr 6×His tag expression plasmid pET-28b (Merck), transformed into chemically competent E. coli BL21 Star (DE3) (Invitrogen), and incubated overnight at 37°C with shaking (220 rpm) in LB broth containing 50 μg/ml Km. The next day, cultures were diluted 1:20 into fresh LB–50 μg/ml Km and grown to an optical density at 600 nm (OD600) of 0.6, and recombinant protein overexpression was induced with isopropyl β-d-1-thiogalactopyranoside (IPTG) at a final concentration of 1 mM for 4 h. Bacteria were pelleted by centrifugation at 3,220 × g for 10 min and stored at −20°C prior to UDP-glucose 6-dehydrogenase enzymatic assays.

UDP-glucose 6-dehydrogenase enzymatic assay.

UDP-glucose 6-dehydrogenase assays were performed as described previously (42). Following IPTG induction of recombinant protein expression in E. coli BL21 Star (DE3) described above, bacterial pellets from 10-ml cultures were resuspended in 1 ml of phosphate buffer (50 mM Na2HPO4 · KH2PO4, pH 7.0). Bacterial cells were mechanically disrupted on ice by sonication with the 550 Sonic Dismembrator (Fisher Scientific) and a microtip probe (20 30-s bursts on setting 4.5, with 30-s rests on ice between bursts). Bacterial debris was pelleted by centrifugation at 13,000 × g for 10 min at 4°C, and the supernatant was harvested for use as crude enzyme. The protein concentration of the crude extract was determined using a Bio-Rad detergent-compatible (DC) protein assay kit. Enzymatic assays were performed in 96-well flat-bottom plates (Corning) by adding 5 μl of crude enzyme to 195 μl of 50 mM phosphate buffer (Na2HPO4 · KH2PO4, pH 7.0) containing 33 mM MgCl2, 5 mM dithiothreitol (DTT), 5 mM UDP-glucose (Sigma-Aldrich), and 0.5 mM NAD (Sigma-Aldrich). The reduction of NAD at 340 nm was monitored spectrophotometrically at 37°C using a SpectraMax 250 (Molecular Devices), with measurements taken every 30 s for 1 h. The enzymatic reaction rate was calculated from the initial linear portion of the curve (reduction of NAD versus time). The net change in A340 per minute (total change − background) was divided by the molar absorptivity of NADH at 340 nm (6,220 M−1 cm−1) and the path length (0.6 cm for Costar 96-well flat-bottom plates), multiplied by the reaction volume (2 × 10−6 liters), and then divided by the total protein in the crude enzyme extract (mg). The specific enzyme activity of UDP-glucose 6-dehydrogenase was expressed as micromoles of NADH produced per min per mg of protein.

HA capsule quantification.

Two independent assays were used to quantify HA capsule expression in mid-logarithmic-phase cultures. The first method measured cell-associated HA polysaccharide concentration using an HA quantitative test kit (Corgenix), as previously described (31). In the second method, we assessed HA capsule expression by flow cytometry using hyaluronan-binding protein (HABP) (Calbiochem). Bacteria were grown to an OD600 of ∼0.4, pelleted by centrifugation at 3,220 × g for 10 min, and resuspended in HEPES buffer (pH 7.4) containing 5 mM CaCl2, 2.5 mM MgCl2, and 0.1% bovine serum albumin (BSA) (HEPES++–0.1% BSA) to an OD600 of 0.4 (∼1 × 108 CFU/ml). A total of 100 μl of this bacterial suspension was pelleted and stained with biotinylated HABP for 20 min at 37°C under shaking conditions. After samples were washed, they were incubated with phycoerythrin (PE)-conjugated streptavidin (SA) (Jackson ImmunoResearch) for 30 min at room temperature. After a final wash, bacteria were resuspended in HEPES++–0.1% BSA and analyzed by flow cytometry. Data represent pooled values from two independent experiments performed in triplicate and normalized to the SA-PE control.

Bioinformatic analyses.

The M1T1 theoretical proteome (i.e., all predicted gene products of the M1T1 genome) was searched for similarity to HasA, HasB, and HasC by BLAST-P similarity analysis (2). In addition, the M1T1 GAS genome was rescreened against these three proteins for any potential unannotated proteins by tBLAST-N analysis (2). Operon similarity and chromosomal clustering/colocalization analyses were performed by the Compare Region tool of the SEED database (http://pubseed.theseed.org/seedviewer.cgi) (37). Sequence comparison and phylogenetic analyses were performed on the Phylogeny.FR server (http://www.phylogeny.fr/) (20). Briefly, MUSCLE (25) was used for multiple sequence alignment, PhyML (30) was used for maximum-likelihood phylogenetic distance and branch support value calculations, and, finally, maximum-likelihood phylograms were drawn by FigTree (http://tree.bio.ed.ac.uk/software/figtree).

Superposition of the theoretical HasB2 structure on the resolved three-dimensional (3D) HasB structure (8) was performed using the Cn3D visualization program (46), available at the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/). Functional domains were identified by searches against Pfam database (http://pfam.sanger.ac.uk/). Transmembrane domains were predicted by searching the TMHMM server, version 2.0 (http://www.cbs.dtu.dk/services/TMHMM/). Signal peptide prediction was undertaken using the SignalP, version 4.0, server (http://www.cbs.dtu.dk/services/SignalP/).

Statistical analyses.

Capsular expression levels, HABP binding, and UDP-glucose 6-dehydrogenase assays were compared by one-way analysis of variance (ANOVA). Statistical significance was accepted at a P value of <0.05. All statistical analyses were performed using GraphPad Prism, version 5.0b (GraphPad Software Inc.).

RESULTS

Capsular expression levels of hasA and hasB mutants.

Previous work reported essential roles for both HasA (hyaluronate synthase) and HasB (UDP-glucose 6-dehydrogenase) in capsule production (3, 18). We set out to verify these findings using individual has gene mutants in the genetic background of M1T1 GAS. Compared to the WT, the ΔhasA mutant was deficient in cell-associated HA capsule (Fig. 1A), corroborating an essential role for hasA in GAS capsule biosynthesis (18). In contrast, precise allelic replacement of the hasB gene with the chloramphenicol acetyltransferase (cat) gene in the WT M1T1 chromosome reduced, but did not abolish, capsule production (Fig. 1A). These results indicated (i) that hasB was not essential for HA capsule synthesis and (ii) that M1T1 GAS must express an additional enzyme with functional UDP-glucose 6-dehydrogenase activity.

Fig 1.

Fig 1

HasB is not essential for capsule production. (A) Quantitation of capsule expression of mid-log-phase M1T1 GAS WT and single hasA and hasB mutant strains. Data denote the means ± standard errors of the means of pooled data from two independent experiments performed in duplicate. Asterisks indicate values that are statistically significantly different (***, P < 0.001). bd, below detection. (B) Genomic organization of the has operon and hasB2 gene, which encodes a putative HasB paralog in M1T1 GAS. Schematic representations of the genomic regions are not drawn to scale. (C) A maximum-likelihood phylogram of HasB2 and a representative set of its homologs indicate a clear distinction between HasB and HasB2. Branch support values are indicated. The plasmid-encoded HasB homolog in Bacillus anthracis seems to be equally distant to both paralogs.

Genome-wide screening for a HasB paralog.

A previous report on the Has operon of Streptococcus zooepidemicus suggested the possibility of a hasB paralog in GAS (6). To identify a functional HasB paralog in the M1T1 GAS genome, we used a computational genome-wide screening analysis of published GAS genomes. BLAST-P interrogation of all predicted GAS proteins with the HasB sequence from M1T1 GAS strain MGAS5005 (NCBI protein accession number YP_283215.1) as a query identified a putative UDP-glucose 6-dehydrogenase, designated M5005_Spy0449 (NCBI accession number YP_281812.1), which shares 45.3% amino acid sequence identity with HasB (Fig. 2A). The gene encoding M5005_Spy0449, here designated hasB2, consists of 1,158 bp (385 amino acids) and is located in a distinct genomic region ∼0.46 Mbp upstream of the hasABC synthesis operon (Fig. 1B). This region is highly conserved among all GAS genome sequences and consists of a small open reading frame (ORF) encoding a hypothetical protein, hasB2, and a mefE homolog encoding a predicted macrolide efflux protein. Interestingly, the extended region surrounding hasB2 is dissimilar in GAS strains (Fig. 1B) and is disrupted by a short mobile element, with combined phage- and plasmid-like genes (Table 1 and Fig. 1B). Examination of the Atomic Regulon Data, computed from published microarray results (http://pubseed.theseed.org/seedviewer.cgi?page = AtomicRegulon&genome = all), indicates that the three genes (the ORF, hasB2, and mefE) tend to be coexpressed in GAS under various conditions, suggesting that they may form one operon. In addition, hasB2 transcription is unchanged in covRS mutants (data from reference 4), suggesting that hasB2 expression may not be under regulation by the CovRS two-component system.

Fig 2.

Fig 2

Alignment and 3D overlay of HasB and HasB2. (A) ClustalW alignment of HasB (GenBank GeneID 3571024) and its paralog HasB2 (GenBank GeneID 3572465) from serotype M1T1 GAS strain MGAS5005 (43). HasB2 is 45.3% identical to HasB at the amino acid level. Asterisks denote identical residues; periods indicate similar residues. Residues implicated in catalysis (yellow), NAD(H) hydrogen bonding (green), UDP-sugar binding (blue), and the dimer partner (red) are highlighted. The gray amino acid is implicated in catalysis and NAD(H) hydrogen bonding, while the orange amino acid is implicated in UDP-sugar binding (8). (B) HasB2 is predicted to have structural similarity to HasB. Superposition of HasB2 on the resolved 3D structure of HasB (8) was performed with Cn3D software (46). Sequence conservation is shown as follows: identical residues, red; similar or nonidentical residues, blue). Amino acid residues in the catalytic domain (T118, E141, E145, K204 N208, C260, and D264 of HasB) are indicated in yellow, beta-sheets are in purple, and alpha helices are in green (based on Campbell et al. [8]).

Table 1.

The has operon and hasB paralog genetic locus in different GAS serotypes

Serotype Representative isolate Genetic profile
hasA hasB hasC hasB2 mefE Contiguous mobile element
M2 MGAS10270 + Truncated + + +
M3 MGAS315 + + + + +
M6 MGAS10394 + + + + +
M12 MGAS2096 + + + + +
M28 MGAS6180 + + + + +
M1 SF370 + + + + + +
M1 MGAS5005 + + + + + +
M5 Manfredo + + + + + +
M18 MGAS8232 + + + + + +
M49 NZ131 + + + + + +

The hasB and hasB2 genes are ubiquitous and highly conserved among GAS strains (Table 1); however, hasB2 was not detected in other streptococcal or enterococcal species, except for Streptococcus pseudoporcinus (Table 2). On the other hand, hasABC is conserved in many streptococci and still present in some bacilli (Table 2), although in a different order (hasACB). Phylogenetic analyses demonstrate that hasB is well conserved in bacteria across the phylogenetic tree, including E. coli, Enterococcus, and some streptococci (Fig. 1C). The hasB2 gene is distinct from hasB genes (Fig. 1C), suggesting that hasB2 arose as a result of gene duplication in GAS or was acquired by horizontal gene transfer, possibly from S. pseudoporcinus or another unsequenced bacterial strain or species.

Table 2.

Presence/absence profiles and gene order of members of the hasABC and hasB2 operons in closely related streptococci and other species

Species has operon order Gene profile (% similaritya)
Nearby mobile element(s)
hasA hasB hasC Short ORF hasB2 mefE- like
S. pyogenes hasABC + + + + + +b Phage/plasmid-like element near hasB2
S. equi hasABC + (75) + (63) +
S. uberis hasAB. . . hasCc + (74) + (60) +
S. parauberis hasAB. . . hasCc + (71) + (63) +
S. pneumoniae hasBAC +/−d (26) +/−d (56) +/−d Transposon elements around hasBAC or hasB
S. suis NAg + (60) Transposon-like elements near hasB
Enterococcus faecalis + (36) + (50)e +e Phage/transposon elements around hasAB
S. thermophilus + (36) + (50) Phage/transposon elements around hasAB
Bacillus cereus hasACB + (51) + (24) + Mobile elements or remnants around hasACB
Bacillus anthracis hasACB + (58) + (24)f + +f Mobile elements or remnants around hasACB
S. pseudoporcinus NA + (57) + + + (67) +
Bacillus halodurans + (48)
Exiguobacterium sibiricum + (49)
a

Percent similarity of homologs was calculated on the amino acid levels.

b

Only if present next to hasB2.

c

hasC is not adjacent to hasB but the genes are separated by only three ORFs.

d

hasB and hasA are present next to hasC in some strains while in others hasB and hasC seem to be separated, and hasA is absent.

e

The E. faecalis version of HasB is also 43% similar to HasB2.

f

The B. anthracis HasB is 26% similar to S. pyogenes HasB2.

g

NA, no operon or genes are not contiguous.

The predicted size for HasB2 is 43.4 kDa, which is in good agreement with the SDS-PAGE size estimate following T7 overexpression of hasB2 in E. coli (∼42 kDa) (data not shown). HasB2 lacks putative signal peptides and transmembrane domains, similar to HasB (data not shown). Interrogation of the Pfam (version 26.0) database reveals that HasB2 and HasB share three distinct UDP-glucose/GDP-mannose dehydrogenase family domains, with predicted active-site residues at C250 and C260, respectively (Table 3) (Fig. 2A). Finally, computational 3D alignments show structural similarities for HasB2 and the published crystal structure of HasB (8) (Fig. 2B), including full conservation of the catalytic residues.

Table 3.

Pfam comparisons of HasB2 and HasB amino acid domains

Family name (accession no.)a Description Amino acid region (E value)b
HasB2 HasB
UDPG_MGDP_dh_N (PF03721) UDP-glucose/GDP-mannose dehydrogenase family, NAD binding domain 1–174 (4.5e−39) 1–174 (2.6e−47)
UDPG_MGDP_dh (PF00984) UDP-glucose/GDP-mannose dehydrogenase family, central domain 187–279 (2.6e−25)c 197–290 (2.1e−26)d
UDPG_MGDP_dh_C (PF03720) UDP-glucose/GDP-mannose dehydrogenase family, UDP binding domain 297–383 (1.3e−09) 313–401 (2.8e−11)
a

Pfam database.

b

Start residue and end residue are indicated.

c

Predicted active-site residue, C250.

d

Predicted active-site residue, C260.

HasB2 UDP-glucose 6-dehydrogenase activity.

To account for M1T1 GAS HA capsule production in the absence of a functional HasB enzyme, we hypothesized that hasB2 encodes a UDP-glucose 6-dehydrogenase. To test this hypothesis, the hasB2 and hasB genes from WT GAS were produced as recombinant proteins in E. coli BL21 Star (DE3), and whole-cell lysates were assayed for UDP-glucose 6-dehydrogenase activity. E. coli cell extracts harboring the HasB2 and HasB expression plasmids have detectable UDP-glucose 6-dehydrogenase enzymatic activity after IPTG induction, compared to the plasmid-only control (Fig. 3). These data demonstrate that hasB2 encodes a functional UDP-glucose 6-dehydrogenase.

Fig 3.

Fig 3

HasB2 is a functional UDP-glucose 6-dehydrogenase. Whole-cell lysates containing recombinant HasB and HasB2 were positive for UDP-glucose 6-dehydrogenase activity, compared to the plasmid-only control, as measured spectrophotometrically by the reduction of NAD at 340 nm. Data represent the means ± standard errors of the means of pooled data from two independent experiments performed in triplicate. *, P < 0.05; ***, P < 0.001.

Capsular expression levels of hasB2 mutants.

We constructed hasB2 mutants in WT (yielding a ΔhasB2 strain) and ΔhasB (yielding a ΔhasB ΔhasB2 strain) strains to determine whether HasB2 contributes to capsule synthesis in M1T1 GAS. Capsule expression levels were analyzed by HA-specific enzyme-linked immunosorbent assay (ELISA) (Fig. 4A). The ΔhasB2 mutant exhibited reduced capsule production compared to the WT but had levels significantly higher than either the ΔhasA or ΔhasB strain (Fig. 4A). However, HA synthesis was abolished in the ΔhasB ΔhasB2 double mutant (Fig. 4A), suggesting that hasB2 can contribute to capsule synthesis, albeit at a reduced level compared to hasB. Revertant ΔhasB2R1 and ΔhasB ΔhasB2R1 strains expressed capsule levels equivalent to those of the WT and ΔhasB strains, respectively, confirming that the mutations were specific for hasB2 (Fig. 4A). Flow cytometric analysis with biotinylated HA-binding protein (HABP) revealed that the acapsular ΔhasA strain and ΔhasB ΔhasB2 strain bound reduced levels of HABP, compared to the WT, ΔhasB, and ΔhasB2 strains (Fig. 4B), verifying that the ΔhasB ΔhasB2 strain is capsule deficient. Overall, these data indicate that HasB is not essential for M1T1 GAS capsule synthesis.

Fig 4.

Fig 4

HasB2 contributes to GAS capsule biogenesis. (A) Quantitation of capsule expression in the WT, mutant, and revertant strains propagated to mid-log phase using ELISA (A) and flow cytometric analysis (B) using hyaluronan-binding protein (HABP). ELISA data represent the means ± standard deviations of pooled normalized data from two independent experiments performed in duplicate. Flow cytometry data represent means ± standard deviations of two independent experiments. Asterisks indicate values that are statistically significantly different: *, P < 0.05; ***, P < 0.001. bd, below detection.

DISCUSSION

GAS is a human pathogen of global significance, causing an array of mild noninvasive and life-threatening invasive infections. The GAS cell surface is bound by a thick layer of HA, a glycosaminoglycan capsule that promotes in vivo survival by circumventing recognition by the host immune system (14) and increasing resistance to phagocyte-mediated killing (11, 16, 36, 49). The exact role of HasB, a UDP-glucose 6-dehydrogenase, in GAS HA capsule biosynthesis remains unclear. Here, we demonstrate that HasB is not essential for serotype M1T1 GAS capsule synthesis. Using a combined approach of molecular genetics and bioinformatics, we identify a putative HasB paralog, termed HasB2, and demonstrate that this protein exhibits UDP-glucose 6-dehydrogenase activity in vitro. To our knowledge, this is the first identification of an enzyme outside the hasABC operon with a demonstrated role in GAS capsule biogenesis.

Capsule biosynthesis in GAS is coordinated by the universal and highly conserved hasABC synthase operon (13, 22), originally identified by Dougherty and van de Rijn through Tn916 transposon mutagenesis of encapsulated serotype M18 GAS (22). Consistent with previous findings (3, 19), we report that mutagenesis of hasA abolishes HA capsule expression in serotype M1T1 GAS. Prior evidence for an essential role of HasB was indirect. For example, Ashbaugh et al. (3) assumed that hasA and hasB are sufficient for GAS capsule expression based on the observation that hasC is not required for capsule synthesis. However, neither targeted mutagenesis nor complementation experiments were performed to corroborate these claims. In addition, previous characterization of acapsular Tn916-inactivated transconjugants identified a deficiency in UDP-glucose dehydrogenase enzymatic activity, suggesting a key role for hasB in GAS capsule expression (23, 24). However, the lack of UDP-glucose dehydrogenase activity was attributed to a polar effect of Tn916::hasA mutation on hasB expression (23, 24). Finally, insertion of the 16.4-kb Tn916 element into the chromosome may have disrupted the hasABC promoter region at −35 to −10, a major determinant of capsule gene expression levels in GAS (1), impeding expression of the entire hasABC operon. Therefore, the precise contribution of hasB to capsular HA production in GAS remained ambiguous.

Here, we derived a precise hasB allelic exchange mutant in a strain representative of the globally disseminated M1T1 serotype (10). The ΔhasB mutant capsular expression levels were reduced compared to the level in WT M1T1 GAS, but the levels were significantly higher than in the acapsular ΔhasA mutant. In contrast to previous studies (3, 19), these data prove that hasB is not essential for capsule production in serotype M1T1 GAS. We hypothesized that a hasB paralog (6) may compensate for a nonfunctional HasB enzyme, thereby providing substrate for capsule biosynthesis in a ΔhasB strain. This hypothesis is supported by previous observations where HasA and HasB together could reconstitute HA biosynthesis in acapsular GAS mutants, Enterococcus faecalis, and Gram-negative E. coli (19). Expression of constructs producing full-length HasA protein and a nonfunctional truncated HasB protein resulted in detectable capsule production in E. coli K5, which contains an endogenous UDP-glucose dehydrogenase. These data suggest that the E. coli K5 UDP-glucose dehydrogenase may substitute for the nonfunctional streptococcal HasB enzyme (19).

Bioinformatic interrogation of the serotype M1T1 GAS genomic sequence identified a putative HasB paralog, here named HasB2, with 45% amino acid identity to HasB. Expression of hasB2 in E. coli generated a protein of approximately 42 kDa, and whole-cell extracts exhibited similar UDP-glucose 6-dehydrogenase activity to HasB control extracts. These data demonstrate that hasB2 encodes a hitherto unidentified UDP-glucose 6-dehydrogenase of GAS. The contribution of hasB2 to M1T1 GAS capsular biogenesis was confirmed by construction and subsequent analysis of hasB2 mutants. The ΔhasB2 mutant displayed reduced capsule expression compared to the WT, but more capsule than the ΔhasB strain, suggesting that hasB2 plays a secondary role to hasB in capsule synthesis. Nevertheless, hasB2 does contribute to HA capsule production, as evidenced by the acapsular phenotype of the ΔhasB ΔhasB2 double mutant. Complementation of the single and double hasB2 mutants restored capsular expression levels to the WT and ΔhasB strains, respectively, confirming that the phenotypes are due to specific hasB2 mutations and not to pleiotropic mutations or polar effects on gene expression levels.

We used two different HABP-based methodologies (ELISA and flow cytometry) to quantify capsule production. The ELISA-based method provided greater sensitivity and a lower background than the flow method. A possible explanation could be that hyaluronic acid capsule is not covalently attached to the peptidoglycan cell wall and only loosely associated with the bacterial surface. Therefore, during sample preparation for flow cytometric analysis, some capsule may have been lost due to centrifugation at high force during the wash steps, leaving only the tightly associated capsule available for staining and reducing the sensitivity of the assay. In addition, the high background associated with the flow-based method indicates some level of nonspecific HABP binding to intact GAS bacteria, as opposed to results using bacterial extracts in the ELISA method. Overall, the conclusion that can be drawn from these two assays is that hasB is not essential for capsule production, despite the differences in the absolute level of contribution.

The bioinformatic and phylogenetic analyses of both the hasB and hasB2 genes and their associated operons (Fig. 1B and C and Table 2) suggest a clear distinction between the evolutionary histories of both paralogs. While hasB, often associated with hasA, seems to be relatively widespread among streptococci (and has been suggested to have originated from a common streptococcal ancestor [6]), hasB2 seems to have been more recently acquired and is present in at least two streptococcal species (GAS and S. pseudoporcinus). While gene duplication cannot be completely ruled out as the origin of hasB2, the similarity between the HasB2 proteins of GAS and S. pseudoporcinus is higher than that between HasB and HasB2 within the same species, suggesting lateral transfer rather than intragenomic duplication. Moreover, the fact that hasB2, as well as many hasA and hasB orthologs, is often surrounded by mobile element genes like transposon, phage, or plasmid-like genes (Tables 1 and 2), supports a scenario where those genes are horizontally transferred within and between genomes, perhaps to add functionality to UDP-glucose pyrophosphorylase genes (hasC homologs) or provide still undefined biochemical functions. Finally, the presence of hasA and hasB orthologs on the megaplasmids of Bacillus cereus and Bacillus anthracis (49) (Table 2), which also carry transposable element genes, even more strongly supports a horizontal origin of these genes.

In summary, we conclude that HasB is a nonessential enzyme for capsular HA expression in serotype M1T1 GAS. A newly identified HasB paralog (HasB2) with functional UDP-glucose 6-dehydrogenase activity has the capacity to support capsule biosynthesis in the absence of a functional HasB enzyme. The identification of an auxiliary UDP-glucose 6-dehydrogenase emphasizes the indispensable role of capsule in GAS pathogenicity and demonstrates the impact of horizontal gene transfer and gene duplication on the evolving virulence potential of microbial pathogens.

ACKNOWLEDGMENTS

J.N.C. was supported by a National Health and Medical Research Council of Australia Overseas Biomedical Training Fellowship (514639) and Project Grant (APP1033258). V.N. was supported by NIH grants AI077780 and AI48176. N.M.V.S. was supported by NIH/UCSD Immunology Training Grant 5T32AI060536.

Footnotes

Published ahead of print 7 September 2012

REFERENCES

  • 1. Alberti S, Ashbaugh CD, Wessels MR. 1998. Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Mol. Microbiol. 28:343–353 [DOI] [PubMed] [Google Scholar]
  • 2. Altschul SF, et al. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389–3402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ashbaugh CD, Alberti S, Wessels MR. 1998. Molecular analysis of the capsule gene region of group A Streptococcus: the hasAB genes are sufficient for capsule expression. J. Bacteriol. 180:4955–4959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Aziz RK, et al. 2010. Microevolution of group A streptococci in vivo: capturing regulatory networks engaged in sociomicrobiology, niche adaptation, and hypervirulence. PLoS One 5:e9798 doi:10.1371/journal.pone.0009798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Bernish B, van de Rijn I. 1999. Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production. J. Biol. Chem. 274:4786–4793 [DOI] [PubMed] [Google Scholar]
  • 6. Blank LM, Hugenholtz P, Nielsen LK. 2008. Evolution of the hyaluronic acid synthesis (has) operon in Streptococcus zooepidemicus and other pathogenic streptococci. J. Mol. Evol. 67:13–22 [DOI] [PubMed] [Google Scholar]
  • 7. Boulnois GJ, Roberts IS. 1990. Genetics of capsular polysaccharide production in bacteria. Curr. Top. Microbiol. Immunol. 150:1–18 [DOI] [PubMed] [Google Scholar]
  • 8. Campbell RE, Mosimann SC, van De Rijn I, Tanner ME, Strynadka NC. 2000. The first structure of UDP-glucose dehydrogenase reveals the catalytic residues necessary for the two-fold oxidation. Biochemistry 39:7012–7023 [PubMed] [Google Scholar]
  • 9. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685–694 [DOI] [PubMed] [Google Scholar]
  • 10. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 9:724–736 [DOI] [PubMed] [Google Scholar]
  • 11. Cole JN, et al. 2010. M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus. mBio 1(4):e00191–10 doi:10.1128/mBio.00191-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Crater DL, Dougherty BA, van de Rijn I. 1995. Molecular characterization of hasC from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose pyrophosphorylase activity. J. Biol. Chem. 270:28676–28680 [DOI] [PubMed] [Google Scholar]
  • 13. Crater DL, van de Rijn I. 1995. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J. Biol. Chem. 270:18452–18458 [DOI] [PubMed] [Google Scholar]
  • 14. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470–511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Cywes C, Stamenkovic I, Wessels MR. 2000. CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J. Clin. Invest. 106:995–1002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Dale JB, Washburn RG, Marques MB, Wessels MR. 1996. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64:1495–1501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Datta V, et al. 2005. Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection. Mol. Microbiol. 56:681–695 [DOI] [PubMed] [Google Scholar]
  • 18. DeAngelis PL, Papaconstantinou J, Weigel PH. 1993. Isolation of a Streptococcus pyogenes gene locus that directs hyaluronan biosynthesis in acapsular mutants and in heterologous bacteria. J. Biol. Chem. 268:14568–14571 [PubMed] [Google Scholar]
  • 19. DeAngelis PL, Papaconstantinou J, Weigel PH. 1993. Molecular cloning, identification, and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes. J. Biol. Chem. 268:19181–19184 [PubMed] [Google Scholar]
  • 20. Dereeper A, et al. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36:W465–W469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Dinkla K, et al. 2007. Upregulation of capsule enables Streptococcus pyogenes to evade immune recognition by antigen-specific antibodies directed to the G-related α2-macroglobulin-binding protein GRAB located on the bacterial surface. Microbes Infect. 9:922–931 [DOI] [PubMed] [Google Scholar]
  • 22. Dougherty BA, van de Rijn I. 1992. Molecular characterization of a locus required for hyaluronic acid capsule production in group A streptococci. J. Exp. Med. 175:1291–1299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Dougherty BA, van de Rijn I. 1994. Molecular characterization of hasA from an operon required for hyaluronic acid synthesis in group A streptococci. J. Biol. Chem. 269:169–175 [PubMed] [Google Scholar]
  • 24. Dougherty BA, van de Rijn I. 1993. Molecular characterization of hasB from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose dehydrogenase activity. J. Biol. Chem. 268:7118–7124 [PubMed] [Google Scholar]
  • 25. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792–1797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Foley MJ, Wood WB., Jr 1959. Studies on the pathogenicity of group A streptococci. II. The antiphagocytic effects of the M protein and the capsular gel. J. Exp. Med. 110:617–628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB. 1989. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr. Top. Microbiol. Immunol. 145:5–26 [DOI] [PubMed] [Google Scholar]
  • 28. Graham MR, et al. 2002. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc. Natl. Acad. Sci. U. S. A. 99:13855–13860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Gryllos I, et al. 2001. Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol. Microbiol. 42:61–74 [DOI] [PubMed] [Google Scholar]
  • 30. Guindon S, Delsuc F, Dufayard JF, Gascuel O. 2009. Estimating maximum likelihood phylogenies with PhyML. Methods Mol. Biol. 537:113–137 [DOI] [PubMed] [Google Scholar]
  • 31. Hollands A, et al. 2010. Genetic switch to hypervirulence reduces colonization phenotypes of the globally disseminated group A Streptococcus M1T1 clone. J. Infect. Dis. 202:11–19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Johnson DA, et al. 2008. High-throughput phenotypic characterization of Pseudomonas aeruginosa membrane transport genes. PLoS Genet. 4:e1000211 doi:10.1371/journal.pgen.1000211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. 2000. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect. Immun. 68:6362–6369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Kendall FE, Heidelberger M, Dawson MH. 1937. A serologically inactive polysaccharide elaborated by mucoid strains of group A hemolytic Streptococcus. J. Biol. Chem. 118:61–69 [Google Scholar]
  • 35. Levin JC, Wessels MR. 1998. Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol. Microbiol. 30:209–219 [DOI] [PubMed] [Google Scholar]
  • 36. Moses AE, et al. 1997. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect. Immun. 65:64–71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Overbeek R, Bartels D, Vonstein V, Meyer F. 2007. Annotation of bacterial and archaeal genomes: improving accuracy and consistency. Chem. Rev. 107:3431–3447 [DOI] [PubMed] [Google Scholar]
  • 38. Pritzlaff CA, et al. 2001. Genetic basis for the beta-haemolytic/cytolytic activity of group B Streptococcus. Mol. Microbiol. 39:236–247 [DOI] [PubMed] [Google Scholar]
  • 39. Ravins M, et al. 2000. Characterization of a mouse-passaged, highly encapsulated variant of group A Streptococcus in in vitro and in vivo studies. J. Infect. Dis. 182:1702–1711 [DOI] [PubMed] [Google Scholar]
  • 40. Schrager HM, Alberti S, Cywes C, Dougherty GJ, Wessels MR. 1998. Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J. Clin. Invest. 101:1708–1716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Stollerman GH, Dale JB. 2008. The importance of the group A Streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin. Infect. Dis. 46:1038–1045 [DOI] [PubMed] [Google Scholar]
  • 42. Stoolmiller AC, Dorfman A. 1969. The biosynthesis of hyaluronic acid by Streptococcus. J. Biol. Chem. 244:236–246 [PubMed] [Google Scholar]
  • 43. Sumby P, et al. 2005. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J. Infect. Dis. 192:771–782 [DOI] [PubMed] [Google Scholar]
  • 44. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. 2006. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2:e5 doi:10.1371/journal.ppat.0020005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Unnikrishnan M, et al. 2002. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J. Immunol. 169:2561–2569 [DOI] [PubMed] [Google Scholar]
  • 46. Wang Y, Geer LY, Chappey C, Kans JA, Bryant SH. 2000. Cn3D: sequence and structure views for Entrez. Trends Biochem. Sci. 25:300–302 [DOI] [PubMed] [Google Scholar]
  • 47. Wessels MR, Bronze MS. 1994. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc. Natl. Acad. Sci. U. S. A. 91:12238–12242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Wessels MR, Goldberg JB, Moses AE, DiCesare TJ. 1994. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect. Immun. 62:433–441 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. 1991. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc. Natl. Acad. Sci. U. S. A. 88:8317–8321 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Bacteriology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES